Table 5.

Univariable Analyses for Association with Mortality in Patients Without Evidence of Myocardial Infarction by clinical history, EKG, or LGE imaging

Variable	HR	CI	LRχ2	p Value
Age	1.06	1.03–1.09	17.4	<0.0001
Male	0.69	0.40–1.22	1.6	0.21
Duration of AF	0.99	0.99–1.00	0.93	0.33
History of Hypertension	1.58	0.94–2.66	2.91	0.09
History of Prior AF Ablation	0.76	0.39–1.48	0.64	0.42
History of Diabetes Mellitus	2.65	1.49–4.69	11.2	0.0008
History of Obstructive Sleep Apnea	1.56	0.94–2.02	2.28	0.16
History of Valvular Heart Disease	1.60	0.76–3.39	1.53	0.22
History of Heart Failure	2.02	1.19–3.41	6.84	0.009
Beta-blockers	1.43	0.81–2.50	1.56	0.21
Calcium Channel Blockers	0.60	0.30–1.23	1.92	0.17
ACE/ARB Inhibitor	1.42	0.85–2.40	1.77	0.18
Class I Anti-arrhythmic	0.57	0.29–1.10	2.80	0.09
Class III Anti-arrhythmic	1.03	0.61–1.75	0.01	0.89
Diuretic Therapy	1.23	0.65–2.32	0.39	0.53
Statin Use	1.75	1.02–3.03	4.05	0.04
Systolic Blood Pressure	0.99	0.98–1.01	0.10	0.74
Diastolic Blood Pressure	1.01	0.98–1.03	0.81	0.37
Heart Rate	1.01	0.99–1.02	2.17	0.14
Body Mass Index	1.04	0.99–1.10	2.60	0.11
Sinus Rhythm (at presentation)	0.95	0.55–1.63	0.04	0.85
AV Delay	1.00	0.99–1.00	0.11	0.74
QRS Duration	1.01	1.00–1.03	4.81	0.03
QTc Duration	1.01	0.99–1.02	3.32	0.07
Echocardiographic Parameters:
LV Ejection Fraction	0.99	0.97–1.02	0.34	0.56
Estimated PASP	1.03	0.99–1.06	2.51	0.11
LV Diastolic Dimension	0.99	0.94–1.04	0.24	0.62
Left Atrial Dimension	1.02	0.98–1.06	0.84	0.36
Cardiac Magnetic Resonance Parameters:
LV EDV	1.00	0.99–1.01	0.01	0.95
LV ESV	1.00	0.99–1.01	0.25	0.62
LV EF	1.00	0.98–1.03	0.01	0.96
LV Mass	1.00	0.99–1.01	0.13	0.72
LV Mass Index	1.00	0.98–1.02	0.04	0.85
RV EDV	1.00	0.99–1.01	0.26	0.61
RV ESV	1.00	0.99–1.01	0.26	0.61
RV EF	0.98	0.95–1.01	1.78	0.18
Left Atrial Dimension	1.02	0.98–1.06	0.65	0.42
Late Gadolinium Enhancement:
Presence of LGE	4.21	2.18–8.14	18.3	<0.0001
Extent of LGE	1.24	1.13–1.35	22.4	<0.0001